Q1 2021

Source filing unavailable

Q1 2021 · —

Revenue—

Net Income

-$1.47M

N/M vs Q1 2020

EPS Diluted

-$0.21

no prior Q1 2020 on file

Operating Cash Flow-$547,138—

Same quarter

Metric	Q1 2021	Q1 2020
Net Income	-$1.47M	-$1.28M
EPS Diluted	-$0.21	—

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Acurx Pharmaceuticals, Inc. · CIK 1736243 · Engraved from SEC EDGAR